Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Free cash flow margin
Bio-Techne Corp's free cash flow margin over the twelve months to 30 June 2026 was 21.7%. Over the past ten years it has ranged from 19.0% (fiscal 2023) to 33.1% (fiscal 2021); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 21.7% | 0.63 |
| FY2025 | 21.0% | 0.66 |
| FY2024 | 20.4% | 1.35 |
| FY2023 | 19.0% | (6.34) |
| FY2022 | 25.4% | (7.71) |
| FY2021 | 33.1% | 12.29 |
| FY2020 | 20.8% | (1.10) |
| FY2019 | 21.9% | (1.36) |
| FY2018 | 23.2% | 0.41 |
| FY2017 | 22.8% | (2.67) |
Against its own ten years
Low 19.0%
High 33.1%
Ten-year median
22.4%
Current reading's percentile
42
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 58.5% |
| HALO Halozyme Therapeutics, Inc. compare | 48.5% |
| TECH Bio-Techne Corp | 21.7% |
| BMRN BioMarin Pharmaceutical Inc. compare | 21.3% |
| CORT Corcept Therapeutics Incorporated compare | 12.9% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | −9.27% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −16.1% |
| BBIO BridgeBio Pharma, Inc. compare | −61.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement